Last reviewed · How we verify
Mysimba
At a glance
| Generic name | Mysimba |
|---|---|
| Also known as | naltrexone/bupropion, pharmacological intervention |
| Sponsor | Carmen Dietvorst |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (PHASE4)
- Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors (MEDFAST-study) (PHASE4)
- Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
- Drug Utilisation of Mysimba/Contrave
- Use of Mysimba in Patients With Weight Regain After Bariatric Surgery (PHASE4)
- Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |